1. Academic Validation
  2. Ynamide Electrophile for the Profiling of Ligandable Carboxyl Residues in Live Cells and the Development of New Covalent Inhibitors

Ynamide Electrophile for the Profiling of Ligandable Carboxyl Residues in Live Cells and the Development of New Covalent Inhibitors

  • J Med Chem. 2022 Aug 11;65(15):10408-10418. doi: 10.1021/acs.jmedchem.2c00272.
Shengrong Li 1 Pengwei Zhang 2 3 Fang Xu 1 Shengcao Hu 1 Jiacong Liu 1 Yi Tan 1 Zhengchao Tu 1 Hongyan Sun 4 Zhi-Min Zhang 1 Qing-Yu He 2 5 Pinghua Sun 1 Ke Ding 1 Zhengqiu Li 1 5
Affiliations

Affiliations

  • 1 School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, China 510632.
  • 2 Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong, China.
  • 3 Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong, China.
  • 4 Department of Chemistry, City University of Hong Kong, Hong Kong 999077, China.
  • 5 MOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou 510120, China.
Abstract

Covalent inhibitors with an electrophilic warhead have received considerable attention due to their remarkable pharmacological properties. However, the electrophilic warhead in covalent drugs is often an α, β-unsaturated amide, and the targets are mainly cysteine or lysine residues. Thus, the development of novel electrophiles that can target other Amino acids is highly desirable. Ynamide, a useful and versatile building block, is commonly employed in the construction of various compounds in organic synthesis. The performance of this functional group in a proteome-wide environment has been studied here for the first time, and it has been shown that it can efficiently modify carboxyl residues in situ and in vitro. Upon incorporation of this ynamide warhead into the pharmacophores of kinase inhibitors, the resulting compound showed moderate inhibition against the EGFR L858R mutant but not against EGFR WT. This novel electrophilic group can be used in the development of new types of covalent inhibitors.

Figures